Pfizer's Ambitions in the Off-Patent World
The pending purchase of Wyeth will accelerate Pfizer's transformation from a mass marketer of superstar drugs into a diversified supplier of targeted therapies, consumer health, and other health care products. It is a major but incomplete step in the search for new growth drivers as Pfizer's cholesterol drug Lipitor--worth a quarter of the Big Pharma's 2008 revenues--loses exclusivity. The company has also restructured existing operations into six business units, the most intriguing of which is the Established Products Business Unit. That division has pulled together Pfizer's off-patent and branded older products into a $10 billion business, albeit one with declining sales. Its leader, David Simmons has the job of reversing the decline and creating a growth story.
You may also be interested in...
The acquisition of Solvay's pharmaceutical unit, completed in February, gave Abbott a substantial branded generics business and strengthened its international presence. Now the company is looking to build on those assets with an enhanced emerging market strategy
Abbott licenses 24 drugs from Zydos and forms an Established Products Division focused on emerging markets.
Ratiopharm would bring market share, geographic diversification, and an attractive OTC business - if the price is right.